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ABSTRACT 
ABSTRAK 
PERBANDINGAN DI ANTARA SERUM FRUKTOSAMIN DAN HbAlc 
SEBAGAI INDEKS KA W ALAN PARAS GLUKOSA SELEPAS MAKAN BAGI 
PESAKIT DIABETES 
Latarbelakang 
Kawalan paras glukosa dalam darah selepas makan adalah penting untuk mengelakkan 
komplikasi mikro dan makrovaskular, mengurangkan rintangan terhadap fungsi insulin, 
memulihkan rembesan hormon insulin, dan mengelakkan komplikasi kepada bayi yang 
akan dilahirkan oleh wanita yang mengidap penyakit diabetes. Kedua-dua pendekatan 
rawatan iaitu; pengurangan paras glukosa semasa berpuasa dan pengurangan paras 
glukosa selepas makan adalah berperanan dalam strategi rawatan diabetes. Rawatan yang 
memberikan penekanan kepada pengawalan paras glukosa selepas makan dikaitkan 
dengan pengawalan paras glukosa secara keseluruhan yang lebih baik. Langkah ini 
mengurangkan kejadian komplikasi kronik pada individu yang mengalami masalah 
diabetes dan gangguan toleransi glukos. Oleh itu suatu kaedah ukuran yang dapat 
mencerminkan paras glukosa selepas makan yangjitu perlu digunakan. 
X 
Objektif 
Objektif kajian ini adalah untuk menilai hubungan di antara serum fruktosamin dan 
HbA I c dengan paras glukosa selepas makan pada pesakit diabetes. 
Kaedah kajian 
Sejumlah 54 pesakit diabetes terlibat dalam kajian keratan rentas, prospektif ini. Semua 
pesakit telah diberikan diet piawai hospital untuk pesakit diabetes (sarapan dan makan 
tengahari). Profil paras glukosa (berpuasa, 2-jam selepas sarapan, sebelum makan 
tengahari dan 2-jam selepas makan tengahari) diambil pada hari yang sama. Perbezaan 
pada paras glukosa dalam plasma pada waktu-waktu tersebut dibandingkan dengan paras 
HbA I c dan fruktosamin yang diambil sekali pada masa berpuasa. 
Keputusan 
Dengan menggunakan analisa "multiple linear regression" dan mengambil faktor HbA I c 
sebagai variabel bersandar dan purata paras glukosa darah pada setiap masa sebagai 
variabel tidak bersandar, didapati hanya paras glukosa darah semasa berpuasa sahaja 
yang berkorelasi secara signifikan dengan HbAlc (r=0.5I4; p=O.OOI). Paras glukosa 
darah semasa berpuasa didapati mempunyai perkaitan yang baik dengan HbA 1 c bagi 
kumpulan tahap glukosa yang terkawal (HbAlc::; 7.0%)(r=0.459; p=0.007) berbanding 
dengan kumpulan tahap glukosa tidak terkawal (HbA lc > 7 .O%)(r=-0.191; p=0.175). 
Paras glukosa darah selepas makan mempunyai perkaitan yang lemah dengan HbA 1 c 
[paras glukosa 2 jam selepas sarapan: r-0.254 (p=0.032) dan paras glukosa 2 jam selepas 
makan tengahari: r = 0.045 (p=0.375)] begitu juga dengan fruktosamin [paras glukosa 2 
xi 
Jam selepas sarapan: r=0.245 (p=0.037) dan paras glukosa 2 jam selepas makan 
tengahari: r=O.l46 (p=O.I46)]. Prevalen "isolated postchallenge hyperglycaemia" adalah 
46%, dengan majoriti (77%) adalah dari kalangan subjek yang mempunyai tahap kawalan 
glukosa darah yang terkawal. Terdapat perkaitan yang kuat di antara paras glukosa darah 
2 jam selepas sarapan dengan paras glukosa sebelum makan tengahari (r=0.89I; 
p=O.OOI). 
Kesimpulan 
Kedua-dua paras HbA I c dan serum fruktosamin didapati tidak mewakili purata paras 
glukosa selepas makan pada pesakit diabetes. Paras glukosa semasa berpuasa 
mempunyai perkaitan secara signifikan dengan HbA I c, oleh itu ia kekal sebagai kaedah 
utama bagi menentukan tahap kawalan menyeluruh glukosa darah. Oleh kerana HbA I c 
dan fruktosamin tidak menunjukkan perkaitan yang baik dengan paras glukosa selepas 
makan, kaedah-kaedah ukuran yang lain yang dapat mencerminkan paras glukosa selepas 
makan perlu dicari. 
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ABSTRACT 
COMPARISON OF SERUM FRUCTOSAMINE AND HbAlc AS AN INDEX OF 
POSTPRANDIAL GL YCAEMIC CONTROL IN DIABETIC PATIENTS 
Background 
Postprandial glycaemic control is important in avoiding microvascular and macrovascular 
complications, lowering insulin resistance, restoring normal insulin secretion, and 
avoiding complications in the offsprings of women with diabetes. It is recommended that 
the treatment of diabetes include methods that lower both fasting and postprandial 
glucose levels. Treatment aimed at controlling postprandial glucose levels is always 
associated with better overall glucose control and thus may result in fewer chronic 
complications in individuals with diabetes and impaired glucose tolerance. In order to 
achieve good postprandial glycemic control, a proper monitoring tool that represents 
postprandial glycaemia status should be used. 
Objective 
To evaluate the relationship between fructosamine and HbA 1 c in assessing postprandial 
hyperglycaemia in diabetic subjects. 
xiii 
Research design and methodology 
A total of 54 diabetic patients were included in this prospective, cross sectional study. All 
subjects were given a standard diabetic hospital diet (breakfast and lunch). Glycaemic 
profiles (fasting, 2-hours postbreakfast, prelunch and 2-hours postlunch plasma glucose) 
over the same day were obtained. The different time points plasma glucose (PG) was 
compared with measurement of HbA I c and fructosamine taken during fasting. 
Results 
In multiple linear regression analysis with HbA I c as dependent variable and mean blood 
glucose at each time points as independent variable, only FPG remained significantly 
correlated with HbAic (r=0.5I4; p=O.OOI). FPG was well correlated with HbAlc in 
controlled glycemic group (HbAic S 7.0%) (r=0.459; p=0.007) but not in uncontrolled 
(HbAlc > 7.0%) group (r=-0.19I; p=O.l75). Postprandial blood glucose was poorly 
correlated with HbAlc [2-hours postbreakfast: r= 0.254 (p=0.032) and 2-hours postlunch: 
r=0.045 (p=0.375)] and serum fructosamine [2-hours postbreakfast: r=0.245 (p=0.037) 
and 2-hour postlunch: r=O.l46 (p=O.l46)]. The prevalence of isolated postchallenge 
hyperglycaemia in the study population was 46%, with majority (77%) of them within the 
controlled glycemic group. There was a strong correlation between 2-hours postbreakfast 
PG and prelunch PG (r=0.891; p=O.OOI). 
XIV 
Conclusion 
Both HbA I c and serum fructosamine did not reflect mean postprandial blood glucose in 
our diabetic subjects. Fasting plasma glucose was significantly correlated with HbA I c 
and thus remained a good predictor of overall glycaemic control. Since both HbA I c and 
fructosamine did not correlate well with postprandial blood sugar, other markers of 
postprandial glycaemia need to be found. 
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CHAPTER ONE 
CHAPTER1 
INTRODUCTION 
Diabetes is a significant illness that is becoming prevalent in Malaysia and most parts of 
the world including both developed and developing countries. Numerous studies 
indicates that it is a major contributor to heart disease, stroke, end-stage renal disease, 
blindness, lower extremity amputation and significant impairment of nervous system. The 
main aims of therapy for diabetics are to relieve symptoms of hyperglycaemia or 
hypoglycaemia and to prevent the long-term complications from tissue damage (Table 
1.1 ). 
Table 1.1: The chronic complications of diabetes 
Complication 
Macroangiopathy 
(arteriosclerosis, myocardial 
disease) 
Microangiopathy 
(retinopathy, nephropathy, 
capillary basement 
membrane thickening) 
Neuropathy 
Diabetic cataract 
Collagen change 
Possible causes 
Hyperglycaemia 
Hyperlipidemia 
Hyperinsulinemia 
Smoking 
?Increased growth hormone level 
?Platelet and other vascular factors 
Hyperglycaemia 
Protein (basement membrane) 
glycosy lation 
Insulin deficiency 
Hyperglycaemia 
Sorbitol accumulation 
Deficient myoinositol 
Myelin glycosylation 
Hyperglycaemia 
Sorbitol accumulation 
Protein glycosylation 
glycosylation 
Adapted from Ledingham, J.G.G. and Warrell, D.A. (2000) 
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It has been shown that intensive insulin regimens to attain strict glycaemic control will 
slow down the development of microvascular complications in type I diabetic patients as 
well as in type 2 diabetic patients. Studies such as United Kingdom Prospective Diabetes 
Study (UKPDS) and the Diabetes Control and Complication Trial (DCCT) have led to 
the conclusion that intensive glucose control with insulin or sulfonylureas markedly 
reduces the risk of microvascular complications (The UKPDS Group I998; The DCCT 
Research Group I993). 
1.1 Effects of intensive versus conventional glycaemic control 
Herman (I999) in a systematic review assessing the impact of control of blood glucose in 
people with type I or type 2 diabetes concluded that intensive treatment compared with 
conventional treatment reduced the development and progression of microvascular 
complications. 
1.1.1 Microvascular and neuropathic complications 
Wang et al. (I993), before the publication of DCCT result, had conducted a systematic 
review of I6 small randomized controlled trials comparing intensive with conventional 
treatment in people with type I diabetes, with follow up ranging from 8 to 60 months. In 
the intensive therapy group, the risk of retinopathy progression was lower after more than 
two years therapy (odds ratio 0.49, 95% confidence interval 0.28-0.85; p=O.Oll). The risk 
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of nephropathy progression was also decreased significantly (odds ratio 0.34, 95% CI 
0.20-0.58; p<O.OO 1 ). Three subsequent longer term randomized controlled trials have 
repeated and extended these findings. The Diabetes Control and Complication Trial 
(DCCT) compared intensive with conventional treatment over 6.5 years in 1441 people 
with type I diabetes (The DCCT Research Group 1993). Patients were divided into two 
groups, 726 with no retinopathy at baseline (the primary-prevention cohort) and 715 with 
mild retinopathy (the secondary-intervention cohort) and were randomly assigned to 
intensive or conventional therapy. In the primary-prevention cohort, intensive therapy 
reduced the adjusted mean risk for the development of retinopathy by 76% (95% 
confidence interval, 0.62-0.85), as compared with conventional therapy (Figure 1.1). In 
the secondary-intervention cohort, intensive therapy slowed the progression of 
retinopathy by 54% (95% confidence interval, 0.39-0.66) and reduced the development of 
proliferative or severe nonproliferative retinopathy by 4 7% (95 percent confidence 
interval, 0.14-0.67)(Figure 1.2). 
The Kumamoto study compared intensive versus standard treatment in 110 people with 
insulin treated type 2 diabetes over six years (Ohkubo et al. 1995). The UKPDS is a 20-
year, multicenter, prospective, randomized, interventional trial of 5102 newly diagnosed 
type 2 diabetes patients. The study compared intensive versus standard treatment. The 
relative risks of retinopathy, nephropathy and neuropathy were all reduced in all these 
studies. 
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60 
.s 50 
s:: 
G) 
·~ 40 
0.. 
0 
30 Q) 
i 
-c 20 (I) 
f:! 
~ 10 
0 
0 1 
Conventional 
Intensive 
2 3 4 5 
Year of Study 
375 
342 
220 
202 
6 7 
79 
78 
8 
Adapted from DCCT Research Group (1993) 
9 
52 
49 
Cumulative incidence of a sustained change in retinopathy in patients 
with IDDM receiving intensive or conventional therapy in the 
primary .. prevention cohort 
4 
.!3 
c (1) 
~ 
0.. 
0 
CD 
~ .., 
c: 
CD 
E 
G) 
D.. 
60 
50 
40 
30 
20 
10 
0 
0 1 
Conventional 
Intensive 
2 3 4 5 
Year of Study 
348 
354 
324 
335 
6 
. -- r----r 
7 
128 
136 
8 9 
79 
93 
Adapted from DCCT Research Group (1993) 
Figure 1.2 Cumulative incidence of a sustained change in retinopathy in patients 
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1.1.2 Macrovascular outcomes 
In the Diabetes Control and Complications Trial, intensive treatment reduced the relative 
risk of any major macrovascular event from 0.8 to 0.5 events per 100 patient years 
(relative risk reduction 41%, 95% confidence interval 10% to 68% )(DCCT 1993). In the 
Kumamoto study, the number of major cerebrovascular, cardiovascular and peripheral 
vascular events in the intensive treatment group was half that of the conventional 
treatment group (0.6 versus 1.3 events per 100 patient years), but the event rates in this 
small trial were low and the results were not significant (Ohkubo et al. 1995). 
The efficacy of these regimens (intensive glucose control) required an accurate method to 
estimate the degree to which this was achieved. 
1.2 Monitoring glucose control 
Blood and urine glucose testing and urine ketone testing has been used since long ago as 
they are easy, readily available and cheap. The tests could be done at home as part of 
self-monitoring program. They provided useful information for day-to-day management 
of diabetes. However, these tests could not provide the patient and health care team with 
a quantitative and reliable measure of glycaemia over an extended period of time. 
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There are five other useful measurements for defining diabetic control: 
I) The mean blood glucose concentration (MBG) 
MBG is measured in clinical trials by the mean of six daily values obtained before 
breakfast, mid-morning, before lunch, mid-afternoon, before dinner, and before sleep. 
Clinically, this has been replaced by the more simple measurement ofHbAic. In some 
cases, however, there was a disparity between the HbA I c values and MBG values based 
on the usual four times a day blood glucose measurements. 
2) The degree to which blood glucose concentrations fluctuate within the same day 
can be formally measured as the mean amplitude of glycaemic excursions (MAGE) 
(Service et al. I970). 
3) The degree to which blood glucose concentrations fluctuate from day to day can 
be formally measured as the mean of daily differences (MODD) (Molnar et al. 1972). 
4) HbAlc 
The most widely used clinical test is measurement of blood glycated hemoglobin (also 
called hemoglobin A I c, glycohaemoglobin and glycosylated haemoglobin [HbA I c ]). 
Hemoglobin A 1 c is a measure of the degree to which hemoglobin is glycosylated in 
erythrocytes and is expressed as a percentage of total hemoglobin concentration. It 
reflects the exposure of erythrocytes to glucose in an irreversible and time- and 
concentration-dependent manner. HbA 1 c levels provide an indication of the average 
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blood glucose concentration during the preceding 2-3 months, incorporating both pre-
and postprandial glycaemia. 
Hemoglobin formed in new red blood cells enters the circulation without any glucose 
attached. However, red cells are freely permeable to glucose. As a result, glucose 
becomes irreversibly attached to hemoglobin during the life of the red cell at a rate 
dependent upon the prevailing blood glucose. Several million red cells are destroyed 
every day, while an equal number of new ones are formed. Thus, the average amount of 
HbAic changes in a dynamic way and reflects the mean blood glucose over the previous 
six to eight weeks (Nathan & Goldstein 1984). Because blood glucose concentrations 
vary widely during a 24-h period and from day to day in diabetes, the measurement of 
HbA I c is the most accepted indicator of long-term glycaemic control. However, the 
HbA I c level does not provide a measure of the magnitude or frequency of short-term 
fluctuations of blood glucose, which are particularly great in type I diabetes. 
Several analyses have shown a strong correlation between HbA 1 c and MBG (r ~ 0.81-
0.95), with each I% change in HbA1c corresponding to a change in MBG of~ 35 mg/dl. 
This relationship was demonstrated in the Diabetes Control and Complications Trial (The 
DCCT Research Group I987). A comparison was made between the mean blood glucose 
derived from seven measurements a day (before and 90 minutes after each of the three 
major meals, and before bedtime) and the HbA1c value in 278 patients with IDDM. A 
strong correlation was noted, such that a HbAlc value of 7 percent represents a MBG of 
about 150 mg/dL (8.3 mmol/L), and a HbAlc value of9 percent represents a MBG about 
8 
210 mg/dL (11.7 mmol/L). DCCT also has shown that the HbA1c value can be referred 
to predict the risk for the development of many of the chronic complications in diabetes, 
analogous to using cholesterol determinations to predict the risk for development of 
cardiovascular disease. The American Diabetic Association ( 1995) has recommended that 
HbA 1 c testing should be performed routinely in all patients with diabetes, first to 
document the degree of glycaemic control at initial assessment, then as part of continuing 
care. 
5) Fructosamine 
Many proteins other than hemoglobin also undergo nonenzymatic glycation, leading to 
the formation of advanced glycosylation end products which may play a direct role in the 
development of diabetic microvascular complications. The plasma concentration of some 
of these proteins can also be used to estimate glycaemic control, and the term 
fructosamine has been applied to the ketoamines formed in this process (Armbruster 
1987). 
Several different methods are available for measuring plasma fructosamine (Armbruster 
1987). Most (including colorimetric assays) are simpler, cheaper and more precise than 
assays for HbA 1 c. There is generally a good correlation between fructosamine and 
HbA I c values (Baker et al. 1985; Koskinen et al. 1987). Plasma fructosamine 
measurement is cheaper and easier, though it reflects shorter-term control compared to 
HbAic, which is more expensive and technically difficult assay. Unlike HbAlc, 
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ftuctosamine has not yet been shown to be related to the risk of the development or 
progression of chronic complications of diabetes (American Diabetic Association 2000). 
1.3 Postprandial blood glucose 
Postprandial hyperglycaemia, or elevated mealtime glucose, is common in people with 
type 2 diabetes, yet often goes undetected. In an analysis by Erlinger et al. (200 1 ), overall 
postprandial hyperglycaemia was present in 74% of those with diagnosed diabetes. While 
present in virtually all (99%) of diabetic adults under suboptimal glycaemic control 
(HbA1c ~ 7.0%), it is also common (39%) among those under optimal control (HbAlc < 
7.0%). Similar patterns were observed in those undiagnosed diabetes. Isolated 
postprandial hyperglycaemia (2 hours glucose~ 200 mg/dl and fasting glucose < 126 
mg/dl) was present in 9.8% of adults with undiagnosed diabetes. 
In the management of diabetes, health care providers usually assess glycaemic control 
with fasting plasma glucose (FPG) and premeal glucose measurements, as well as by 
measuring HbA I c. The goal in the management of patients with type 2 diabetes is to 
control fasting plasma glucose and glycosylated hemoglobin (HbA 1 c) levels. In patients 
with well-controlled diabetes (HbA 1 c <7%, or within 1% of normal) or glucose 
intolerance (fasting plasma glucose level <126 mg/dL, and a 2-hour plasma glucose of 
140 to 200 mg/dL after 75 g of oral glucose), postprandial hyperglycaemia has a greater 
effect on HbAlc than fasting glucose levels. Jovanovic (1999) reported that the 
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postprandial glucose level at 1 hour is the best predictor of HbA 1 c in patients with well-
controlled type 2 diabetes mellitus. In addition, a French study of patients with type 2 
diabetes showed that glucose concentrations at 2 and 5 hours after a meal were better 
predictors of the HbA I c than prebreakfast or pre lunch values (A vi goon et al. 1997). 
Patients spend a significant part of their day in the postprandial state. These 
mealtime/postprandial elevations contribute to overall blood glucose levels as measured 
by HbAic. However, because diabetes management has traditionally focused on fasting 
plasma glucose levels (measurement of glucose in the absence of food), the surges in 
glucose that typically occur in type 2 diabetes patients after eating are often not 
evaluated. It is also noted that the postprandial glucose level is one of the most under-
recognized and under-treated condition in diabetes. 
1.4 The importance of glucose control 
In the fasting state, the suppression of insulin production and stimulation of glucagon 
production control the concentration of blood glucose. These processes allow the liver to 
mobilize glucose from its glycogen stores and synthesize glucose from amino acids and 
pyruvate (gluconeogenesis). In addition, when insulin levels are low, the uptake of 
glucose by muscle is minimized, and adipocytes release free fatty acids. This homeostatic 
mechanism effects a stable plasma glucose level in the fasting state so that the brain, 
which has no energy stores, has a sufficient supply of nutrients for normal activity. 
II 
In the fed state, insulin is released in two phases. The first phase, a short, small burst 
released on food intake or an increase in plasma glucose concentration, preempts and 
decreases the postprandial glucose elevation. Later, a more sustained, second-phase 
insulin release directly proportional to the plasma glucose elevation occurs. In response 
to this biphasic release of insulin, the liver takes up glucose, converting it to glycogen 
(animal starch). The muscle and adipose tissues also take up glucose, storing it as 
glycogen and triglycerides, respectively. Furthermore, the production of free fatty acids 
in adipocytes is suppressed. The loss of first-phase insulin release has adverse metabolic 
and physiologic consequences, even if the second-phase release is adequate or even 
excessive. 
1.4.1 First-phase insulin release 
One of the earliest changes in the development of type 2 diabetes is the loss of first-phase 
insulin release, which occurs with fasting glucose levels of about 110 mg/dL. The loss 
can be documented by measuring plasma insulin concentrations over the 10 minutes 
immediately after an intravenous glucose load, calculated on the basis of the patient's 
weight. Lack of first-phase insulin release, an excellent predictor of both types of 
diabetes, is thought to be the earliest sign of the adverse effects of hyperglycaemia on 
insulin-producing ~-cells and insulin-sensitive tissues (glucotoxicity) (Poitout & 
Robertson 1996). When the first-phase insulin response fails, plasma glucose levels rise 
sharply after a meal. Initially, this precipitates an increased stimulation of second-phase 
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insulin release that, in the early stages of glucose intolerance, may lead to postprandial 
hypoglycaemia resulting from elevated plasma insulin remaining after the nutrients have 
disappeared (Mitrakou et al. 1992). High insulin levels also cause downregulation of the 
insulin postreceptor pathways on the muscle and fat cells, thus increasing insulin 
resistance (Mandarino et al. 1984). 
The higher glucose level in islet cells prompts a decrease in glucose-transporter activity, 
resulting in a reduction of insulin release (Rossetti et al. 1990), which is reversed by a 
decrease in plasma glucose level. If there is no decrease, the prolonged hyperglycaemia 
will eventually cause an accelerated loss of insulin-producing ~-cells in both type I and 
type 2 diabetes (Poitout et al. 1996). Thus, metabolic loss of first-phase insulin release 
results in postprandial hyperglycaemia, an increase in insulin resistance, and a further 
decrease in insulin production. 
The fasting blood glucose concentration is often used to monitor progress since it 
correlates well with HbA 1 c values (Howe-Davies et al. 1980). Fasting blood glucose 
concentrations are fairly stable in type 2 diabetic patients, but can vary by about 15 
percent from day to day (Ollerton et al. 1999). Therapeutic goals for HbA1c and 
preprandial glucose levels have been established based on the results of controlled 
clinical trials. Unfortunately, the majority of patients with diabetes fail to achieve their 
glycaemic goals. It was noted that elevated postprandial glucose (PPG) concentrations 
may contribute to suboptimal glycaemic control (American Diabetic Association 2001 ). 
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An important role for postprandial glucose monitoring with therapy aimed at achieving 
postprandial glucose targets is suggested by teleologic argument, biochemical 
information, epidemiologic study and limited clinical data (Buse & Hroscikoski 1998). 
Postprandial hyperglycaemia is also one of the earliest abnormalities of glucose 
homeostasis associated with type 2 diabetes and is markedly exaggerated in diabetic 
patients with fasting hyperglycaemia. 
1.4.2 Effect of postprandial glucose levels on microvascular complications 
The effects of postprandial hyperglycaemia on the development of microvascular 
complications of diabetes have been well documented. There is evidence that 
uncontrolled glycaemic peaks activate protein kinase C, the enzyme that may link 
hyperglycaemia to microvascular complications (Koya & King 1998). Elevated glucose 
levels lead to increased intracellular synthesis of diacylglycerol, which, in conjunction 
with elevated intracellular calcium, activates protein kinase C 939. The activity of protein 
kinase C impairs contraction of smooth muscle cells or pericytes, increases production of 
basement membrane materials, and enhances cell proliferation and capillary permeability. 
Thus, activation of protein kinase C by postprandial hyperglycaemia could be responsible 
for microvascular complications that may be developing even in the early stages of 
diabetes (Koya & King 1998). 
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Data from the National Health and Nutrition Examination Survey in 1998, showed that 
patients who had 2-hours postprandial glucose levels of 194 mgldL had a threefold 
increase in the incidence of retinopathy, despite normal fasting glucose levels. Studies of 
Pima Indian and Egyptian populations revealed a similar increase in the incidence of 
retinopathy in subjects with normal fasting glucose levels but 2-hours postprandial 
glucose values of >200 mg/dL (American Diabetic Association 1997). 
The development of microvascular complications in patients with type 2 diabetes has 
been documented in a number of clinical trials. In a long-term study of complications in 
patients who had type 2 diabetes for more than 25 years, Mohan et al. ( 1996), reported 
that postprandial glucose levels were associated with diabetic nephropathy. In a study of 
Pima Indian subjects, hyperfiltration, a precursor of diabetic nephropathy, in subjects 
with impaired glucose tolerance was found to increase with the onset of type 2 diabetes 
(Nelson et al. 1999). In a population study, Beghi et al. (1997) showed that elevated 
fasting and postprandial glucose levels, as well as prolonged disease duration, were 
associated with an increased incidence of diabetic neuropathy. Other studies which had 
shown that postprandial hyperglycaemia is associated with higher risk of microvascular 
complications includes studies performed by de Veciana et al.( 1995), McCance et 
al.(l994) and Engelgau et al.(1997). 
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1.4.3 Postprandial glucose levels and macrovascular complications 
The glycaemic threshold for the development of macrovascular complications is lower 
than that for microvascular complications, so there is more evidence for an association 
with postprandial glycaemia. Postprandial glucose elevations are associated with 
postprandial hyperinsulinemia and higher plasma levels of triglycerides, chylomicrons, 
chylomicron remnants and free fatty acids. In addition, high postprandial glucose levels 
result in protein and cellular glycosylation. Glycosylated LDL particles are more easily 
oxidized and taken up by macrophages through the scavenger receptor. This leads to 
higher foam cell production and ultimately, atherosclerotic plaque. In addition, 
glycosylated LDL also stimulates platelet aggregation. Glycosylated HDL is less efficient 
than nonglycosylated HDL in transporting cholesterol back to the liver for metabolism. 
Additionally, the formation of advanced glycosylated end products in the collagen of the 
vessel wall itself may directly stimulate or accelerate the atherosclerotic process (Bucala 
et al. 1995). Acute increases in plasma glucose also stimulate the production of free 
radicals, another factor involved in the atherosclerotic process (Habib et al. 1994). 
Excessive postprandial plasma glucose levels have also been associated with transient 
hypercoagulability resulting from increased thrombin production and decreased 
fibrinogen breakdown. These, in tum, result from the overproduction of plasminogen 
activator inhibitor, which directly inhibits tissue plasminogen activator activity. Control 
of postprandial hyperglycaemia reverses this hypercoagulable state (Ceriello et al. 1993). 
The Honolulu Heart Study (Donahue et al. 1987) found that the risk of CAD correlated 
with plasma glucose levels measured 1 hour after a 50-g oral glucose load. The incidence 
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of CAD was twice as high in patients with postprandial plasma glucose levels between 
157 and 189 mg/dL compared to those with levels <144 mg/dL, and the incidence of 
sudden death was doubled with postprandial plasma glucose levels > 151 mg/dL. The 
Whitehall Study of British male civil servants showed that plasma glucose levels >96 
mg/dL 2 hours after a meal were associated with a twofold increase in mortality from 
CAD (Fuller et al. 1980). Another British study, the Islington Diabetes Survey, reported 
that the incidence of major CAD (defined as major electrocardiographic changes or 
myocardial infarction) was 17% in subjects with a 2-hour postprandial glucose level 
between 120 and 180 mg/dL, compared with 9% in subjects with levels <120 mg/dL 
(Jackson et al. 1992). The Bedford Survey showed that protection from CAD was lost in 
patients with elevated postprandial glucose (Jarrett et al. 1982). By studying the 
progression of CAD in young men with previous myocardial infarction, Bavenholm et al. 
( 1998) found that fasting and postprandial plasma glucose levels were independently 
related to disease progression. The Oslo Study indicated that the nonfasting plasma 
glucose level was a predictor of fatal stroke in diabetic patients, with the risk increasing 
by 13% for each 18-mg/dL elevation in postprandial glucose (Haheim et al. 1995). The 
Diabetes Intervention Study also showed that postprandial, not fasting, hyperglycaemia 
was an independent risk factor for myocardial infarction and cardiac death (Hanefeld et 
al. 1997). The risk of cardiovascular disease and all cause mortality increases with 
increasing postprandial blood glucose values (Lowe et al. 1997). 
The Hoorn Study documented an increased risk of peripheral vascular disease in elderly 
patients with diabetes and in subjects with impaired glucose tolerance (Beks et al. 1995). 
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Ankle to brachial pressure indices< 0.9 were found in 7% of nondiabetic subjects, 9.5% 
of subjects with impaired glucose tolerance, 15.1% of patients with newly diagnosed 
diabetes, and 20.9% of patients with established type 2 diabetes. After logistical 
regression analysis and correction for other cardiovascular risk factors, the 2-hour 
postprandial plasma glucose value remained an independent risk factor for peripheral 
vascular disease, whereas plasma insulin did not (Beks et al. 1995). 
Overexposure to insulin in response to postprandial hyperglycaemia has been shown to 
be a risk factor for cardiovascular events. The Paris Prospective Study found that 
postprandial hyperinsulinemia was a better predictor for fatal CAD than either 
hyperglycaemia or diabetes (Fontbonne et al. 1991). Similarly, the Helsinki Policemen 
Study revealed an independent association between fatal and nonfatal CAD events and l-
and 2-hour postprandial insulin levels that was stronger than that with fasting plasma 
insulin levels (Pyorala 1985). Finally, a report suggested an association between increase 
in postprandial levels of insulin and decrease in cognitive function in women aged 55 
years and over (age adjusted regression coefficient -0.10 per 50 mU/1 insulin; 95% CI -
0.16 to -0.04)(Stolk et al. 1997). 
Another factor associated with postprandial hyperglycaemia is postprandial 
hyperlipidemia. Elevated triglyceride levels after a meal predict the development of CAD 
and are associated with carotid artery atherosclerosis in nonobese white subjects (Sharrett 
et al. 1995). Therefore, a reduction of postprandial glucose levels, which also reduces 
plasma insulin and lipids after a meal, could reduce the incidence of CAD. 
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The European DECODE study also found that an elevated postprandial glucose level was 
a significantly better predictor of risk of death than the fasting plasma glucose level 
(DECODE 1999). 
1.4.4 Postprandial glucose levels and pregnancy outcomes 
The effect of postprandial hyperglycaemia was also demonstrated in pregnant women in 
studies by Jovanovic-Peterson et al. (1991). They reported that in pregnant patients with 
diabetes, postprandial hyperglycaemia is more closely related to fetal macrosomia than 
preprandial hyperglycaemia in pregnancies complicated by preexisting diabetes. That 
observation led to recommendations for both preprandial and postprandial blood glucose 
monitoring in women with gestational diabetes (Jovanovic 1995). Similarly, Combs et al. 
(1992), reported that there was a strong correlation between macrosomia and high 
postprandial glucose levels occurring during the 29th to 32nd week of pregnancy. 
In a trial reported by de Veciana et al. (1995), of 66 gestational diabetic women who 
monitored either prep ran dial or postprandial blood glucose levels, the final HbA 1 c level 
was significantly lower in women who used postprandial monitoring. Moreover, the rate 
of cesarean-section and the number of large-for-gestational-age infants were significantly 
lower in women who used postprandial monitoring to achieve improved HbA 1 c level. 
Demarini et al. (1994) studied two groups of pregnant women with different target levels 
of postprandial glucose, <120 and <140 mg/dL, respectively. Neonatal hypoglycaemia 
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occurred at a higher frequency in babies born to women in the <140 mg/dL group. 
Because of these studies, the American Diabetes Association now recommends 
monitoring both fasting and 1-hour plasma serum glucose levels during pregnancy 
(Jovanovic 1995). 
1.5 Methods of controlling postprandial hyperglycaemia 
Postprandial glycaemic control is important in avoiding microvascular and macrovascular 
complications, lowering insulin resistance, restoring normal insulin secretion and 
avoiding complications in the offspring of women with diabetes. It is recommended that 
the treatment of diabetes include methods that lower both fasting and postprandial 
glucose levels. 
Strategies for the management of diabetes have evolved considerably over the last few 
years. We have moved from an era where glycaemic control was aimed primarily at 
avoiding the symptoms associated with hyperglycaemia (polyuria, polydipsia, weight loss 
and fatigue) to an era where the primary objective is to attain near normal glycaemic 
control in an effort to prevent or delay the microvascular and macrovascular 
complications of diabetes. This switch in emphasis, and the parallel developments in 
pharmacologic agents and lifestyle intervention techniques, translates into greater 
attention to glycaemic control in the postprandial state. Therefore, therapies that focus on 
lowering postprandial glucose are beneficial and also important in reducing diabetic 
complications and mortality and currently an important focus for therapy. 
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These had led to the development of newer oral hypoglycaemic agents or insulin with the 
target of controlling postprandial hyperglycaemia. In type I diabetes, postprandial glucose 
levels can be controlled only with very fast-acting insulin, such as insulin lispro (Feinglos 
et al. 1997; Holleman & Hoekstra 1997) and also insulin aspart (Home et al. 1998). New 
antidiabetic drugs in development, such as the injectable amylin analog pramlintide and 
glucagon-like insulinotropic polypeptide (GLIP), target the suppression of postprandial 
hyperglycaemia (Joubert et al. 1990; Schmitz et al. 1997). These drugs slow gastric 
emptying and suppress glucagon production. In patients with type 2 diabetes who require 
none or just one evening or nighttime injection of intermediate-acting insulin to control 
the fasting glucose level, an oral agent capable of stimulating an insulin release sufficient 
to cover the meal or delay -the absorption of glucose from the intestine (bolus agents) 
should be used. Drugs with these properties should be used in combination with oral 
agents that lower insulin resistance, decrease hepatic glucose production, or stimulate 
insulin production (basal agents). This therapy can be described as oral basal-bolus 
therapy for type 2 diabetes, in contrast to injection-based basal-bolus therapy using 
insulin for type 1. Among other available agents, the alpha glucosidase inhibitors, with 
acarbose serving as the prototype, specifically reduces insulin requirements. Not 
coincidentally, acarbose's primary hypoglycaemic effect is on postprandial glucose 
levels. By altering the postprandial rise in glucose, acarbose spares the amount of insulin 
needed. 
Bolus drugs include acarbose, miglitol, repaglinide, and possibly glimepiride. Examples 
of basal drugs are troglitazone, pioglitazone, rosiglitazone, metformin, long-acting 
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sulfonylureas, and intermediate and long-acting insulins. It is easier to achieve the long-
term HbAlc goal~ 7% using basal-bolus therapy, because at this level of control, the 
biggest contributor to HbA1c values is the postprandial glucose level (Jovanovic 1999). 
1.6 Relationship between postprandial blood glucose with HbAlc and fructosamine 
Regardless of the drugs available, for optimal postprandial glycaemic control, patients 
must monitor their glucose levels after eating a meal. When diabetes is poorly controlled, 
only preprandial glucose readings are necessary. However, once control is achieved, it is 
important to monitor glucose levels both before and after meals. This allows for 
appropriate adjustments of bolus drug administration to reach postprandial glycaemic 
goals and to maximize the patient's protection from diabetic complications. 
The relative contributions of FPG and PPG to HbAtc have been studied only recently. In 
general, fasting plasma glucose, postprandial blood glucose, and especially mean blood 
glucose (MBG) concentrations, defined by the average of multiple measurements of 
glucose taken throughout the day, are highly correlated with HbAtc· FPG has been 
correlated with overall glucose control, as measured by HbAlc (Graf 1978; McCance 
1988). 
So far, the method commonly used (HbAlc and serum fructosamine) is validated only for 
monitoring of mean blood glucose (MBG) and fasting blood glucose (Howe-Davies et al. 
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1980). In Malaysia, the measurement of glycated albumin (fructosamine), which is 
substantially cheaper than HbA I c has not been widely adopted. It is only done for 
monitoring gestational diabetes. 
It has long been accepted that the 'gold standard' marker of overall glycaemic control in 
diabetes mellitus is the level of glycated haemoglobin (HbA I c). It is the preferred marker 
for glycaemic control compared to fructosamine. It is, however, an expensive and not 
readily available in certain hospitals in this region. Plasma fructosamine measurement is 
cheaper and easier, and also it reflects shorter-term glycaemia. Furthermore, diabetic 
patients can be monitored more closely and frequently in diabetic clinics, rather than 
every 3 months or so. However, trials only focused on fasting or premeal blood glucose 
rather than postprandial blood glucose. For these reasons this study has been designed to 
evaluate the relationship of HbA I c and serum fructosamine as an index of postprandial 
glycaemic control. 
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CHAPTER TWO 
CHAPTER TWO 
OBJECTIVES 
2.1. General objective 
To evaluate the relationship between fructosamine and HbA 1 c as a predictor 
of postprandial hyperglycaemia in diabetic subjects. 
2.2. Specific objectives 
I) To determine the frequency of subjects with normal FPG but with 
abnormal postprandial blood glucose (isolated postchallenge 
hyperglycaemia) 
2) To compare the correlation between fructosamine and HbAlc with 
postprandial hyperglycaemia 
3) To evaluate the relationship between postprandial plasma glucose with 
other time point plasma glucose 
4) To evaluate the differences of plasma glucose between the controlled and 
uncontrolled glycaemic groups 
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